drugset
drugset / Trial / NCT03661983

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

NCT03661983 ↗

Phase 4 Terminated 36 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).

Timeline

Start
2018-10-13
Primary completion
2020-06-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 2 mg Oral
Subject Aripiprazole Other / unclassified 5 mg Oral
Subject Aripiprazole Other / unclassified 10 mg Oral
Subject Aripiprazole Other / unclassified 20 mg Oral

Indications

Tourette syndrome